



Dihydrotestosterone in Amyotrophic Lateral Sclerosis –The missing link ?

Journal:	<i>Muscle and Nerve</i>
Manuscript ID	MUS-20-0568
Wiley - Manuscript type:	Clinical Research Short Report
Date Submitted by the Author:	22-Jul-2020
Complete List of Authors:	sawal, nishit; Government Medical college and Hospital. Sector 32. Chandigarh., Neurology Kaur, jasbinder; government Medical college and Hospital, Chandigarh, Biochemistry Kaur, Kamaljeet; Government medical college and hospital, Chandigarh, Biochemistry Gombar, Satinder; government Medical College and Hospital, Chandigarh, Anaesthesia and Intensive care
Keywords:	ALS, amyotrophic lateral sclerosis, body mass index, motor neuron, motor neuron disease
Free Text Keywords:	

SCHOLARONE™
Manuscripts

1
2
3 **Title – Dihydrotestosterone in Amyotrophic Lateral Sclerosis –The missing link ?**
4

5 **Running title – Dihydrotestosterone in ALS Pathogenesis.**
6
7

8
9 **Authors-**
10

- 11
12 1. Dr Nishit Sawal. D.M.[Neurology]. Assistant Professor [Neurology]. Government .
13 Medical college and Hospital , Chandigarh. drnishitsawal@gmail.com. Phone - 0172-
14 2673506 –Corresponding Author.
15 Conceived the entire idea , recruited patients and wrote the manuscript .
16 The author has no conflict of interest and no financial disclosure to make.
17
18
19
20
21 2. Dr Jasbinder Kaur. M.D.[Biochemistry]- Professor and Head –Department of
22 Biochemistry . Government . Medical college and Hospital , Chandigarh.
23 jasbinderkaur@yahoo.co.in. Phone –0172-2675401 .
24 Did the CSF ELISA testosterone and dihydrotestosterone evaluation of all patients and
25 controls and helped in writing the manuscript.
26 The author has no conflict of interest and no financial disclosure to make.
27
28
29
30
31 3. Kamaljeet Kaur . Masters in Biochemistry. Biochemist. Department of
32 Biochemistry . Government . Medical college and Hospital , Chandigarh.
33 Kkaur3189@gmail.com. Phone –0172-2675402 .
34 Did the CSF ELISA testosterone and dihydrotestosterone evaluation of all patients and
35 controls and helped in writing methods portion of the manuscript.
36 The author has no conflict of interest and no financial disclosure to make.
37
38
39
40
41
42
43 4. Dr Satinder Gombar .M.D.[Anesthesia] Professor and Head. Department of Anaesthesia
44 and Intensive care. Government . Medical college and Hospital , Chandigarh
45 drsgombar57@gmail.com. Phone –0172-2671219 .
46 Recruited Controls for the study.
47 The author has no conflict of interest and no financial disclosure to make.
48
49
50
51

52 **Acknowledgements:** Prof. Narinder Kumar, Professor and Manish Goyal , Research
53 Fellow . Department of Statistics, Panjab University ,Chandigarh for performing the
54
55
56
57
58
59
60

1
2
3 statistical analysis of the results.
4
5
6

7 Word count

8
9 Abstract- 225

10
11 Text- 1489

12
13 References- 24

14
15 Tables- 2

16
17 Figure – 1

18
19 Supplemental tables - 4

20
21 Corresponding Author- Dr Nishit Sawal. D.M.[Neurology]. Assistant Professor

22
23 [Neurology]. Government . Medical college and Hospital , Chandigarh.

24
25 drnishitsawal@gmail.com.

26
27
28 Ethical publication statement –All the authors confirm that they have read the Journal's
29 position on issues involved in ethical publication and affirm that this report is consistent
30 with those guidelines.
31
32

33 Disclosure of Conflicts of interest- None of the Authors has any disclosures to make.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Cover Letter

We, the authors of the research article **“Dihydrotestosterone in Amyotrophic Lateral Sclerosis –The missing link ?”** state our intent to submit our manuscript to Muscle & Nerve for consideration of publication.

We also hereby furnish a disclosure stating that this manuscript is not under consideration elsewhere.

For Peer Review Only

Abstract

Introduction – Testosterone has been postulated to be involved in ALS causation. Increased incidence of ALS is seen in soccer players and jobs requiring physical endurance.

Methods- CSF levels of free testosterone and dihydrotestosterone were measured in 13 ALS patients [7 males , 6 females] and 22 controls [12 males, 10 females].

Results - CSF free testosterone levels did not show any significant differences but there was significant difference in CSF dihydrotestosterone levels between male ALS patients and controls ($p<0.001$) and between female ALS patients and controls ($p<0.001$).

Discussion – Reduced CSF levels of DHT were associated with ALS in our study. DHT might play a role in maintaining integrity of motor neurons. Entire intracerebral DHT is formed from intracerebral testosterone as DHT cannot traverse the BBB. Possible explanation is that in ALS patients, lesser amount of testosterone is able to breach the BBB and enter the central neural axis. There would be inadequate negative feedback suppression of LH at the level of anterior pituitary owing to lesser DHT formed consequently. As a result of higher LH levels , testosterone levels would rise in peripheral testosterone fraction [the fraction outside the BBB] and this would explain the various physical attributes of ALS patients like lower ratio of the index and ring finger lengths (2D:4D ratio) , increased incidence of early onset alopecia etc.

Keywords –

ALS- Amyotrophic Lateral Sclerosis;DHT- dihydrotestosterone; BBB- blood brain barrier; LH- Luteinizing hormone; CSF-Cerebrospinal fluid;SHBG- sex hormone binding globulin .

Introduction

Amyotrophic Lateral Sclerosis is a progressive neurodegenerative disorder¹. Androgens may play some role in causation of ALS² based on observations like preponderance of male to female patients with ALS, sparing of neurons of cranial nerves III, IV, and VI and Onuf's nucleus in ALS that lack androgen receptors² and X-linked spinobulbar muscular atrophy (Kennedy's disease) resulting from a trinucleotide repeat expansion in the androgen receptor gene³.

Athletes engaging in sports like Soccer which require high degree of endurance have increased susceptibility to ALS. Studies have found that both male and female athletes in aggressive contact sports have higher testosterone levels⁴.

A study⁵ found that post-menopausal female ALS patients had significantly higher serum total testosterone and serum free testosterone concentrations than age matched post menopausal controls. Vivekananada et al⁶ found that ALS patients had lower ratio of the index and ring finger lengths (2D:4D ratio) in comparison with controls. 2D:4D ratio is dependent on prenatal testosterone levels.

In our study, we measured concentrations of testosterone and dihydrotestosterone in cerebrospinal fluid (CSF) of ALS patients and compared it with normal controls.

Methods

CSF levels of free testosterone and dihydrotestosterone were measured in 13 ALS patients [7 males and 6 females] and in 22 controls [12 males and 10 females] using enzyme-linked immunosorbent assay (ELISA) based kits after taking informed consent. CSF samples were collected in morning between 9:00 AM and 11:00 AM as studies⁷ have shown that testosterone concentrations vary during the day. Clearances from Institutional Research and Ethical Committees was obtained (No-IEC/2018/90).

Statistical analysis - Students t- test was applied to evaluate whether there was any significant difference between the 2 groups.

Inclusion criteria used for patients:

1
2
3 a) Patients fulfilling the diagnosis of Clinically definite ALS and clinically probable ALS
4 as per El Escorial Criteria (EEC)⁸.
5
6
7

8
9 Inclusion criteria used for controls:
10

11
12 a) Controls were enrolled from surgery, gynecology and obstetrics and orthopedics wards. CSF
13 was obtained from male and female controls undergoing lumbar puncture for spinal anesthesia.
14
15

16
17 Exclusion criteria used :
18

19 a) Subjects not giving consent for study . b) Subjects suffering from cryptorchidism , testicular
20 malignancy or any other testicular pathology . c) Subjects taking anabolic hormones. d) Subjects
21 suffering from pituitary or adrenal disease. e) Female subjects with Polycystic ovarian disease
22 (PCOD) f) Subjects with family history of ALS or any form of motor neuron disease or
23 Frontotemporal dementia [FTD].
24
25
26
27

28 29 **Results**

30
31 Clinical and demographic data and CSF concentrations of Free testosterone and
32 dihydrotestosterone in ALS patients and controls are summarized in tables 1 and 2 and in
33 supplemental tables and Fig 1.
34
35

36
37 There was no significant difference in CSF testosterone values between male ALS patients and
38 controls [$p=0.344$] and between female ALS patients and controls[$p=0.917$]. However CSF
39 dihydrotestosterone concentrations demonstrated a significant difference between male ALS
40 patients and controls [$p<0.001$] and between female ALS patients and controls[$p<0.001$] with
41 DHT concentrations being significantly lower in ALS patients.
42
43
44
45
46
47
48

49 **Discussion**

50
51 In our study we demonstrated significantly decreased CSF dihydrotestosterone levels in ALS
52 patients . Studies on how testosterone and its metabolites exert a negative influence on LH
53 release have demonstrated the following observations –
54
55
56
57
58
59
60

1
2
3 Radioactively labelled dihydrotestosterone was given intravenously to six rhesus monkeys and it
4 was found that that no radioactively labelled DHT could be found in CSF post-injection thus
5 demonstrating that dihydrotestosterone has minimal penetration across the Blood-brain barrier
6 [BBB]⁹. A study¹⁰ on castrated male monkeys found that even in presence of very high,
7 supraphysiological serum levels of DHT, CSF concentrations of DHT stayed very low.
8

9
10 The above findings are in contrast to CSF penetration dynamics of testosterone. Studies¹¹
11 have shown that CSF levels of testosterone are equal to those of unbound serum testosterone
12 levels with the entire CSF testosterone being unbound. Also it is known that testosterone crosses
13 the BBB (blood brain barrier) only in the unbound state.
14

15 The study¹¹ also found that a sharp increase in serum total testosterone, unbound serum
16 testosterone and CSF testosterone coincided with an abrupt fall in serum LH (Luteinising
17 hormone) levels. Abbott et al¹⁰ had demonstrated in their study that intracerebral DHT can
18 suppress serum LH levels and also concurred with a previous study by Sholl et al¹² that a
19 majority of DHT within the brain comes from the precursor testosterone.
20

21 Patients with 5 alpha reductase type 2 deficiency have high circulating LH levels despite having
22 normal or elevated serum levels of testosterone. However these patients have reduced serum
23 DHT levels¹³ but no increased risk of ALS.
24

25 Studies¹⁴ suggest that estradiol derived from intracerebral testosterone is the main hormone
26 that provides negative feedback at the hypothalamic level while at the level of the anterior
27 pituitary, both DHT and estradiol, both derived from intracerebral testosterone, are required
28 for negative LH feedback.
29

30 Total testosterone and free non-SHBG bound testosterone have been found to have a diurnal
31 circadian variation with highest levels being seen in the morning and lowest in the evening
32 ^{15,16,17}. A study¹⁵ documented elderly males having reduced testosterone levels as compared to
33 younger males and also an more pronounced difference between the circadian excursion of total
34 serum testosterone levels between the two groups.
35

36 Studies^{18,19} have shown that both total testosterone and free testosterone concentrations
37 decrease with ageing while SHBG levels increase with ageing. Obesity, insulin resistance,
38 metabolic syndrome and dyslipidemia have a strong association with low serum levels of total
39 testosterone, free testosterone and sex hormone binding globulin (SHBG)^{18,19}. SHBG levels
40 play a more important role in the development of insulin resistance/metabolic syndrome than
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 total or free testosterone does. Many studies ²⁰ have suggested that ALS patients have a lower
4 pre-morbid body mass index as compared to controls and have been leaner, fitter in their life as
5 compared to controls. In other words , being obese or having a higher BMI is protective against
6 development of ALS in later life. Studies ²¹ have found that having a higher pre-morbid BMI
7 predicts a better prognosis in ALS.
8
9

10
11 There is emerging evidence that high carbohydrate/high fat hypercaloric diets may improve
12 survival in ALS patients²².
13

14
15 Breedlove et al ²³ in their study on motor neurons found that following systemic administration
16 of radioactive androgens , DHT accumulated to a greater degree in the spinal motor neuron
17 nuclei than testosterone and unlike testosterone , DHT concentrations in spinal motor neurons
18 did not show any sex difference. This shows that DHT is an essential, integral component of sex
19 steroid machinery in the motor neurons .It was earlier widely believed that the hypothalamic–
20 pituitary–gonadal axis in humans remains quiescent after birth until the onset of pubertal
21 activation and that LH and FSH night-day rhythms begin just before the onset of puberty.
22 However studies using ultra-sensitive assay methods²⁴ have shown that circulating
23 gonadotrophin concentrations and diurnal Rhythms of Luteinizing Hormone, Follicle-
24 Stimulating Hormone, Testosterone, and Estradiol Secretion exist and are well established in
25 prepubertal children as young as 4.6 years .
26
27

28
29 Based on data from the above studies , we postulate that DHT or one of its metabolites is
30 probably integral to survival of motor neurons and in ALS, it is lack of DHT in the motor
31 neurons which leads to their death. CSF levels of DHT are probably the final arbiter of LH
32 release at the level of anterior pituitary . Entire DHT fraction in the central neural axis is derived
33 from the testosterone fraction which penetrates the BBB since DHT itself cannot penetrate BBB.
34 When testosterone concentrations breach a certain “critical” threshold, the binding capacity of
35 SHBG (Sex hormone binding globulin) is exceeded and only then does the levels of free ,
36 unbound serum testosterone rise sufficiently to cause the rise in CSF testosterone . This CSF
37 testosterone is converted to dihydrotestosterone and the resultant increase in dihydrotestosterone
38 suppresses LH levels by exerting a negative feedback on LH release . We postulate that in
39 patients who are predisposed to develop ALS , there is a sort of “testosterone resistance” at the
40 level of BBB. In these patients , lesser amount of testosterone is able to breach the BBB and
41 enter the central neural axis. As a result , lesser amount of testosterone is available to 5α
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 reductase type 2 isoenzyme in the anterior pituitary to be converted to DHT and lesser amount of
4 DHT is generated. As a result , there is inadequate negative feedback suppression of LH at the
5 level of anterior pituitary by DHT or its metabolites like 3-alpha diol. As a result of higher LH
6 levels , testosterone levels rise in the peripheral testosterone fraction [the fraction outside the
7 BBB] and this explains the various physical attributes of ALS patients like the lower Ratio of
8 the index and ring finger lengths (2D:4D ratio) , increased incidence of early onset androgenic
9 alopecia, the increased athleticism in the pre-morbid years , the lower BMI in the pre-morbid
10 years (the “always been lean”) phenomenon etc.
11
12
13
14
15
16
17
18
19
20
21

22 **Potential Conflicts of Interest** – None.

23
24 **Source of Funding Statement** – No Funds used.

25
26
27 **Data Availability statement** - The data that support the findings of this study are
28 available on request from the corresponding author. The data are not publicly available due to
29 privacy or ethical restrictions.
30
31
32
33

34 **Abbreviations used** - ALS- Amyotrophic Lateral Sclerosis; DHT- dihydrotestosterone; BBB-
35 blood brain barrier; LH- Luteinizing hormone; CSF-Cerebrospinal fluid; SHBG- sex hormone
36 binding globulin; BMI-Body Mass Index, PCOD-Polycystic Ovarian disease..
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Chio A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, Traynor BG. Prognostic factors in ALS: A critical review. *Amyotroph Lateral Scler.* 2009; 10:310–323.
2. Weiner LP ; Possible role of androgen receptors in amyotrophic lateral sclerosis. A hypothesis. *Arch Neurol.* 1980 Mar;37(3):129-31..
3. A.R. La Spada, E.M. Wilson, D.B. Lubahn, A.E. Harding, K.H. Fischbeck; Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy, *Nature* 352 (1991) 77–79.
4. Pillay R M; Athletes' Testosterone Levels by Sports Team: An Exploratory Analysis . Simon Fraser University . 2006.
5. Gargiulo-Monachelli GM et al. Circulating Steroids in Amyotrophic Lateral Sclerosis: Possible Markers of Susceptibility and Outcome; *Horm Metab Res* 2014; 46: 433–439.
6. Vivekananda U , Manjalay Z, J Ganesalingham J , Simms J , E Shaw , P Leigh , R Turner, Al-Chalabi ; Low index-to-ring finger length ratio in sporadic ALS supports prenatally defined motor neuronal vulnerability. *J Neurol Neurosurg Psychiatry* 82, 6 (2011).
7. Goodman, R.L.; Hotchkiss, J.; Karsch, F.J.; Knobil, E.: Diurnal variations in serum testosterone concentration in the adult male rhesus monkey. *Biol. Reprod.* :624-630 (1974).
8. Brooks BR, Miller RG, Swash M, Munsat TL – El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. *ALS and other Motor Neuron Disord* 2000;1:293-299.
9. Marynick, S. P., Havens, W. W., Ebert, M. H , and Loriaux, D. L. (1976). Studies on the transfer of steroid hormones across the blood-cerebrospinal fluid barrier in the rhesus monkey. *Endocrinology* (Baltimore) 99, 400-405.
10. Abbott, D. A., Batty, K. A., Dubey, A. K., Herbert, J. , and Shiers, H. M. (1985). The passage of 5 α -dihydrotestosterone from serum into cerebrospinal fluid and LH negative feedback in castrated rhesus monkeys. *J. Endocrinol.* 104, 325-330.

- 1
2
3 11. Dubey, A. K., Herbert, J., Abbott, D. & Martensz, N. D. (1984). Serum and CSF
4 concentrations of testosterone and LH related to negative feedback in male rhesus
5 monkeys. *Neuroendocrinology* 39, 176-185.
6
7
- 8
9 12. Sholl, S. A., Goy, R. W. & Uno, H. (1982). Differences in brain uptake and metabolism of
10 testosterone in gonadectomized, adrenalectomized and female rhesus monkeys.
11 *Endocrinology* 11, 806-813.
12
13
- 14 13. Martini, L., Celotti, F., & Serio, M. (1979). 5 α -Reductase deficiency in humans: support
15 to the theory that 5 α -reduction of testosterone is an essential step in the control of LH
16 secretion. *Journal of Endocrinological Investigation*, 2(4), 463–
17 464. doi:10.1007/bf03349351
18
19
- 20 14. Chimento A, Sirianni R, Casaburi I, Pezzi V; Role of estrogen receptors and G protein-
21 coupled estrogen receptor in regulation of hypothalamus–pituitary–testis axis and
22 spermatogenesis. *Front Endocrinol (Lausanne)* 2014;5:1.
23
24
- 25 15. Bremner WJ, Vitiello MV, Prinz PN. Loss of circadian rhythmicity in blood testosterone
26 levels with aging in normal men. *J Clin Endocrinol Metab* 1983;56:1278-81.
27
28
- 29 16. Plymate SR, Tenover JS, Bremner WJ; Circadian variation in testosterone, sex hormone-
30 binding globulin, and calculated non-sex hormone-binding globulin bound testosterone in
31 healthy young and elderly men. *J Androl*. 1989; 10: 366– 371.
32
33
- 34 17. Tenover JS, Matsumoto AM, Clifton DK, Bremner WJ. 1988. Age-related alterations in
35 the circadian rhythms of pulsatile luteinizing hormone and testosterone secretion in
36 healthy men. *J Gerontol* 43:M163–M169.
37
38
- 39 18. Gapstur SM, Gann PH, Kopp P, Colangelo L, Longcope C, Liu K. Serum androgen.
40 concentrations in young men: a longitudinal analysis of associations with age, obesity,
41 and race. The CARDIA male hormone study. *Cancer Epidemiol Biomarkers Prev*
42 2002;11:1041–7.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 19. Leifke E, Gorenai V, Wichers C, Von Zur Muhlen A, Brabant G. Age-related
4 changes of serum sex hormones, insulin-like growth factor-1 and sex hormone binding
5 globulin levels in men: cross-sectional data from a healthy male cohort.
6 Clin Endocrinol (Oxf) 2000;53:689–95.
7
8
9
10
11
12
13
14
15 20. Scarmeas N , Shih T . , Stern Y , Ottman R , Rowland LP . Premorbid weight, body mass,
16 and university athletics in ALS . Neurology. 2002 ; 59 : 773 – 5 .
17
18
19
20
21 21. Reich-Slotky R, Andrews J, Cheng B, Buchsbaum R, Levy D, Kaufmann P, et al. Body
22 mass index (BMI) as predictor of ALSFRS-R score decline in ALS patients. Amyotroph
23 Lateral Scler Frontotemporal Degener 2013;14(3):212–6.
24
25
26
27
28 22. A.-M. Wills, J. Hubbard, and E. A. Macklin, “Hypercaloric enteral nutrition in patients
29 with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2
30 trial,” *The Lancet*, vol. 383, no. 9934, pp. 2065–2072, 2014.
31
32
33
34
35 23. Breedlove S.M., Arthur A.P; Differences in the Pattern of Steroid Accumulation by
36 Motoneurons of the Rat Lumbar Spinal Cord. *Jour Comparative Neurology* 215~211-216
37 (1983).
38
39
40
41
42
43 24. Mitamura R, Yano K, Suzuki N, Ito Y, Makita Y, Okuno A. Diurnal rhythms of
44 luteinizing hormone, follicle-stimulating hormone, and testosterone secretion before the
45 onset of male puberty. *J Clin Endocrinol Metab.*1999. 84:29 –37.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1 – Age distribution of ALS patients and controls


ALS patients		Controls	
	Mean Age and range(years)		Mean Age and range(years)
Males	51.57 (30-60)	Males	44.75 (19-62)
Females	59.33 (50-68)	Females	46.50 (25-71)

ALS- Amyotrophic Lateral Sclerosis

Table 2 – CSF Dihydrotestosterone and CSF Testosterone concentrations in male and female ALS patients and controls.

CSF Dihydrotestosterone (pg/ml)			CSF Testosterone(pg/ml)		
Male patients	ALS	Male Controls	Male patients	ALS	Male Controls
	76.2	322.4		0.88	0.99
	99.9	409.8		0.57	1.01
	23.5	310.77		0.86	0.76
	54.56	265		0.41	0.24
	179.8	252.8		0.56	1.08
	33.9	264.31		0.25	0.53
	184.02	462.96		0.47	0.8
		345.12			0.75
		365.4			0.7
		201.01			0.42
		213.13			0.45
		360.61			0.52
CSF Dihydrotestosterone (pg/ml)			CSF Testosterone(pg/ml)		
Female patients	ALS	Female Controls	Female patients	ALS	Female Controls
	10.9	82.81		0.15	0.12
	10	128.96		0.38	0.08
	34.5	184.18		0.02	0.33
	13.3	74.21		0.07	0.02
	10.5	173.8		0.02	0.28
	10.27	71.8		0.15	0.1
		75.8			0.14
		247.47			0.03
		140.2			0.21
		66.2			0.07

pg/ml-picograms per milliliter , CSF-Cerebrospinal fluid, ALS- Amyotrophic Lateral Sclerosis



pg/ml - pico grams per milliliter

DHT-Dihydrotestosterone, T- Testosterone, ALS - Amyotrophic lateral sclerosis.

Blue dots indicate male and female ALS patients, green dots indicate male and female controls.

Plotted on Y axis are levels of Dihydrotestosterone and Testosterone, on X- axis are plotted the study groups- ALS patients and controls.

CSF Dihydrotestosterone(DHT) and Testosterone(T) levels in male and female ALS patients compared with CSF Dihydrotestosterone(DHT) and Testosterone(T) levels in male and female controls.

70x98mm (300 x 300 DPI)